Vericel Corp (VCEL) stock
VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/30254% above fair value
$57.42−2.03 (-3.41%)
Close on Nov 12, 2026Market cap $2.94BP/E 97.3Yield –
Vericel ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Vericel's ebitda for the twelve months ending Sep 30, 2026 was $40.57M, up 138.1% year over year. For fiscal 2025 it was $22.59M, up 125.4% from the year before. The highest annual figure on record is $22.59M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.59M | +125.4% |
| FY2024 | Dec 31, 2024 | $10.02M | – |
| FY2023 | Dec 31, 2023 | -$1.83M | – |
| FY2022 | Dec 31, 2022 | -$13.08M | – |
| FY2021 | Dec 31, 2021 | -$4.89M | -202.8% |
| FY2020 | Dec 31, 2020 | $4.76M | – |
| FY2019 | Dec 31, 2019 | -$9.55M | – |
| FY2018 | Dec 31, 2018 | -$2.48M | – |
| FY2017 | Dec 31, 2017 | -$13.37M | – |
| FY2016 | Dec 31, 2016 | -$17.36M | – |
| FY2015 | Dec 31, 2015 | -$15.08M | – |
| FY2014 | Dec 31, 2014 | -$22.78M | – |
| FY2013 | Dec 31, 2013 | -$20.48M | – |
| FY2012 | Dec 31, 2012 | -$33.11M | – |
| FY2010 | Jun 30, 2010 | -$17.21M | – |
| FY2009 | Jun 30, 2009 | -$15.47M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $15.81M | +147.3% |
| Q2 FY2026 | Jun 30, 2026 | $4.05M | +408.7% |
| Q1 FY2026 | Mar 31, 2026 | -$4.80M | – |
| Q4 FY2025 | Dec 31, 2025 | $25.50M | +27.8% |
| Q3 FY2025 | Sep 30, 2025 | $6.39M | – |
| Q2 FY2025 | Jun 30, 2025 | $797.00K | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.11M | – |
| Q4 FY2024 | Dec 31, 2024 | $19.96M | +43.8% |
| Q3 FY2024 | Sep 30, 2024 | -$1.14M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.71M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.09M | – |
| Q4 FY2023 | Dec 31, 2023 | $13.88M | +94.8% |
| Q3 FY2023 | Sep 30, 2023 | -$3.90M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.79M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.02M | – |
| Q4 FY2022 | Dec 31, 2022 | $7.12M | +44.8% |
| Q3 FY2022 | Sep 30, 2022 | -$5.79M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.98M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.40M | – |
| Q4 FY2021 | Dec 31, 2021 | $4.92M | -62.2% |
| Q3 FY2021 | Sep 30, 2021 | -$4.26M | -204.3% |
| Q2 FY2021 | Jun 30, 2021 | -$3.03M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.49M | – |
| Q4 FY2020 | Dec 31, 2020 | $13.02M | +33.8% |
| Q3 FY2020 | Sep 30, 2020 | $4.09M | +14.4% |
| Q2 FY2020 | Jun 30, 2020 | -$7.81M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.54M | – |
| Q4 FY2019 | Dec 31, 2019 | $9.74M | +54.8% |
| Q3 FY2019 | Sep 30, 2019 | $3.57M | – |
| Q2 FY2019 | Jun 30, 2019 | -$19.83M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.03M | – |
| Q4 FY2018 | Dec 31, 2018 | $6.29M | +288.9% |
| Q3 FY2018 | Sep 30, 2018 | -$1.02M | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.86M | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.90M | – |
| Q4 FY2017 | Dec 31, 2017 | $1.62M | -4.0% |
| Q3 FY2017 | Sep 30, 2017 | -$3.63M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.15M | – |
| Q1 FY2017 | Mar 31, 2017 | -$9.21M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.68M | – |
See a number that looks wrong?